Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paroxysmal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    204 result(s) found for: Paroxysmal. Displaying page 4 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003440-74 Sponsor Protocol Number: ALXN1210-PNH-401 Start Date*: 2020-05-14
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-002589-34 Sponsor Protocol Number: FLECA-ED Start Date*: 2022-12-16
    Sponsor Name:WinMedica S.A.
    Full Title: Μία προοπτική, πολυκεντρική, τυχαιοποιημένη, κλινική δοκιμή για την ασφάλεια και την αποτελεσματικότητα της Φλεκαϊνίδης έναντι της Αμιωδαρόνης για την καρδιοανάταξη της παροξυσμικής Κολπικής Μαρμαρ...
    Medical condition: Καρδιοανάταξη της παροξυσμικής κολπικής μαρμαρυγής στο Τμήμα Επειγόντων Περιστατικών σε ασθενείς με στεφανιαία νόσο χωρίς υπολειπόμενη ισχαιμία και κλάσμα εξώθησης > 35%.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003661 Atrial fibrillation paroxysmal LLT
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003956-19 Sponsor Protocol Number: RA101495-01.301 Start Date*: 2019-02-13
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003671-19 Sponsor Protocol Number: 71534 Start Date*: 2020-01-13
    Sponsor Name:Stichting Epilepsie Instellingen Nederland
    Full Title: Efficacy and safety of hydralazine in combination with valproate to treat hypocretin deficiency in recent onset narcolepsy: a pilot study
    Medical condition: Narcolepsy type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019442-87 Sponsor Protocol Number: DROPPAF Start Date*: 2010-07-02
    Sponsor Name:East Sussex NHS Trust
    Full Title: Dronedarone in pacemaker patients with paroxysmal atrial fibrillation
    Medical condition: Paroxysmal atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002996-18 Sponsor Protocol Number: ATI-2042-CLN-08 Start Date*: 2005-03-10
    Sponsor Name:ARYx Therapeutics Limited
    Full Title: A Phase 2 Pilot Study of the Efficacy of ATI-2042 in subjects with Paroxysmal Atrial Fibrillation and Pacemakers
    Medical condition: Paroxysmal Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    7.0 10050106 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-002966-34 Sponsor Protocol Number: TAK-861-2002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2)
    Medical condition: Narcolepsy without Cataplexy (Type 2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) FR (Completed) IT (Completed) ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-001857-13 Sponsor Protocol Number: NODE-303 Start Date*: 2020-04-09
    Sponsor Name:Milestone Pharmaceuticals Inc.
    Full Title: Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia
    Medical condition: Treatment of Paroxysmal Supraventricular Tachycardia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10034044 Paroxysmal supraventricular tachycardia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) DE (Completed) HU (Completed) DK (Completed) CZ (Completed) SK (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002965-13 Sponsor Protocol Number: TAK-861-2003 Start Date*: 2023-04-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions
    Medical condition: Narcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) IT (Trial now transitioned) ES (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016077-14 Sponsor Protocol Number: RALF1 Start Date*: 2010-11-11
    Sponsor Name:Mika Lehto
    Full Title: Role of ALiskiren, a direct renin inhibitor, in preventing atrial Fibrillation in patients with a pacemaker; RALF Eteisvärinäkuorman määritys sydämentahdistimella aliskireenihoidossa
    Medical condition: Patients who have a pacemaker due to sinus node disease and paroxysmal atrial fibrillation.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067824 Prophylaxis against atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000833-38 Sponsor Protocol Number: ISIS329993-CS6 Start Date*: 2012-06-19
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation
    Medical condition: Atrial fibrillation (AF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005536-17 Sponsor Protocol Number: UX007G-CL301 Start Date*: 2017-05-17
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1...
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000251-39 Sponsor Protocol Number: TAK-994-1504 Start Date*: 2021-08-12
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults Wi...
    Medical condition: Narcolepsy With Cataplexy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011291-29 Sponsor Protocol Number: RACE 3 Start Date*: 2011-08-16
    Sponsor Name:Interuniversity Cardiology Institute of the Netherlands (ICIN)
    Full Title: Routine versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3
    Medical condition: atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002088-18 Sponsor Protocol Number: H3A106104 Start Date*: 2006-10-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028713 Narcolepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) FI (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001654-38 Sponsor Protocol Number: TAK-861-2001 Start Date*: 2023-05-26
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
    Medical condition: Narcolepsy with cataplexy (Narcolepsy Type 1)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) FI (Completed) SE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-001505-93 Sponsor Protocol Number: P11-11 Start Date*: 2013-12-19
    Sponsor Name:Bioprojet Pharma
    Full Title: A MULTI-CENTRE, SINGLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS OF PITOLISANT (BF2.649) IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001430-18 Sponsor Protocol Number: 5101127 Start Date*: 2019-08-12
    Sponsor Name:Kuopio University Hospital
    Full Title: Does postoperative intravenous corticosteroid and intravenous beta blocker management prevent atrial fibrillation after cardiac surgery?
    Medical condition: new onset atrial fibrillation and paroxysmal atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005525-48 Sponsor Protocol Number: AK-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Diakonhjemmet hospital
    Full Title: Potassium infusion for conversion of atrial fibrillation/atrial flutter.
    Medical condition: Atrial fibrillation / atrial flutter
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000865-34 Sponsor Protocol Number: AC-065C202 Start Date*: 2014-09-16
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud's Phenomenon second...
    Medical condition: Raynaud's Phenomenon secondary to Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:22:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA